Data

Click on Protocol Number of interest to view study-related documentation or download data files. (DTMC data files are under development.)
Division Sort descending Study Number Title Investigator(s) Release Date
DTMC NIDA-CSP-1008B A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence Peter Bridge, M.D. Dec 04, 2014
DTMC NIDA-CPU-0002 Double-Blind, Placebo-Controlled, Dose Escalating, Safety and Pharmacology Study With Three Dosages of GBR 12909 in Cocaine Experienced Volunteers Louis Cantilena, Jr., M.D, Ph.D. May 23, 2017
DTMC NIDA-CSP-1018 A Multicenter Safety Trial of Buprenorphine/Naloxone for the Treatment of Opiate Dependence Walter Ling, M.D., Paul J. Fudala, Ph.D., Paul Casadonte, M.D. Sep 02, 2015
DTMC NIDA-CPU-0003 Phase I, Double-Blind, Placebo-Controlled Dose Escalating Assessment of Potential Interactions Between Intravenous Cocaine and RPR 102681 Louis Cantilena, Jr., M.D, Ph.D. May 23, 2017
DTMC NIDA-CSP-1025 Phase 2, Double-Blind, Placebo-Controlled Trial Of Topiramate For The Treatment Of Methamphetamine Dependence Bankole Johnson, DSc., M.D., Ph.D. Sep 02, 2015
DTMC NIDA-CPU-0006 A Phase 1 Parallel-Group, Double-Blind, Placebo-Controlled Cardiovascular and Behavioral Study Assessing Interactions Between Single Doses of Oral Reserpine and Intravenous Methamphetamine Reese Jones, M.D. May 23, 2017
DTMC NIDA-CSP-1026 Phase 2, Double-Blind, Placebo-Controlled Trial Of Modafinil For Methamphetamine Dependence Ahmed Elkashef, M.D. Sep 02, 2015
DTMC NIDA-CPU-0004 Study of Interactions Between GBR 12909 and Cocaine Kathryn Cunningham, Ph.D., John Grabowski, Ph.D. May 23, 2017
DTMC NIDA-CPU-0005 Double-blind, placebo-controlled, safety and pharmacology study with 75 mg dosage of GBR 12909 in cocaine experienced African American Volunteers. Louis Cantilena, Jr., M.D, Ph.D. May 23, 2017
DTMC NIDA-CTO-0001 Phase 2, Double-Blind, Placebo-Controlled Trial Of Reserpine For The Treatment Of Cocaine Dependence Eugene Somoza, M.D. Dec 04, 2014